Skip to content

SPRAVATO® (esketamine) is a prescription medicine, used along with an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD).

SPRAVATO® can also be prescribed to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization, when a healthcare provider determines that hospitalization is needed.

SPRAVATO® is taken as a self-administered nasal spray, under the supervision of a healthcare provider in a healthcare setting.

Treatments are given twice a week for 4 weeks, then maintenance therapy, which is usually once weekly, is customized to the patient’s response.

SPRAVATO® can only be given at a certified healthcare facility with a healthcare provider present. Patients are monitored for at least 2 hours after receiving SPRAVATO®.

Patients may qualify for SPRAVATO® who have major depressive disorder and haven’t responded to at least 2 medications for depression from at least 2 classes of drugs.

The most common side effects are sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space, and time (dissociation).

There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider will check you for signs of abuse and dependence before and during treatment with SPRAVATO®. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.

Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

Yes, Victory Clinic is enrolled in the SPRAVATO® REMS Program. Patients who qualify for SPRAVATO®, must enroll in the SPRAVATO® REMS Program.

Plan for a caregiver or family member to drive you home after taking SPRAVATO®. Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep.

Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.

SPRAVATO® is not for use in children.

Coverage for SPRAVATO® is dictated by your insurance provider.

Once you and your healthcare provider have decided that SPRAVATO® is right for you, SPRAVATO withMe (formerly Janssen CarePath) will help you find the resources you may need, whether you have commercial insurance, government-funded coverage, or no coverage. SPRAVATO withMe can provide information on your insurance coverage for SPRAVATO® and what your potential out-of-pocket costs may be.

Visit https://www.spravato.com/trd/treatment-cost-support to learn more, or call a Care Navigator at 1-844-479-4846, Monday through Friday, from 7:00AM to 7:00PM CT.

Unlike anti-depressant medications, SPRAVATO® does not have the side effects of weight gain and decreased libido.

 How do I pay for TMS or SPRAVATO®?

Many insurance plans cover TMS or SPRAVATO® for treatment resistant depression. If your insurance doesn’t cover treatment, financing is available through Affirm on our RepeatMD app. Contact your insurance to check your eligibility, or you may call or email us with questions.

TRICARE insurance
VA insurance
BlueCrossBlueShield insurance
Back To Top